HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

HighTower Advisors LLC acquired a new stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 50,087 shares of the company’s stock, valued at approximately $168,000. HighTower Advisors LLC owned about 0.06% of Atea Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in AVIR. BML Capital Management LLC grew its stake in Atea Pharmaceuticals by 14.4% in the fourth quarter. BML Capital Management LLC now owns 7,608,312 shares of the company’s stock valued at $25,488,000 after purchasing an additional 958,312 shares in the last quarter. FMR LLC increased its holdings in Atea Pharmaceuticals by 2.8% during the third quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after buying an additional 182,174 shares during the last quarter. State Street Corp increased its holdings in Atea Pharmaceuticals by 0.7% during the third quarter. State Street Corp now owns 1,733,486 shares of the company’s stock worth $5,807,000 after buying an additional 11,566 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Atea Pharmaceuticals by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 659,527 shares of the company’s stock worth $2,209,000 after acquiring an additional 9,370 shares in the last quarter. Finally, Peapod Lane Capital LLC acquired a new stake in Atea Pharmaceuticals in the fourth quarter valued at $1,101,000. Institutional investors own 86.67% of the company’s stock.

Analyst Ratings Changes

Separately, William Blair reiterated an “outperform” rating on shares of Atea Pharmaceuticals in a research note on Friday, March 7th.

Atea Pharmaceuticals Trading Down 3.8 %

AVIR stock opened at $2.79 on Friday. Atea Pharmaceuticals, Inc. has a 1-year low of $2.74 and a 1-year high of $4.15. The business’s 50 day simple moving average is $3.05 and its 200 day simple moving average is $3.25. The firm has a market capitalization of $238.61 million, a PE ratio of -1.35 and a beta of 0.17.

Atea Pharmaceuticals (NASDAQ:AVIR) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). As a group, sell-side analysts predict that Atea Pharmaceuticals, Inc. will post -2.01 EPS for the current fiscal year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.